The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
Int J Oncol. 2012 May;40(5):1483-91. doi: 10.3892/ijo.2012.1353. Epub 2012 Feb 2.
Int J Oncol. 2012.
PMID: 22328338